Open access journal of the Ferrata-Storti Foundation, a non-profit organization
Articles

Improved outcomes of acute lymphoblastic leukemia after allogeneic blood or marrow transplantation with highdose post-transplantation cyclophosphamide in the era of more effective pre-transplant therapy

Division of Hematologic Malignancy, Department of Oncology, Johns Hopkins University, Baltimore, MD
Department of Internal Medicine, Yale University, New Heaven, CT
Division of Biostatistics and Bioinformatics, Department of Oncology, Johns Hopkins University, Baltimore, MD
Division of Hematologic Malignancy, Department of Oncology, Johns Hopkins University, Baltimore, MD
Division of Hematologic Malignancy, Department of Oncology, Johns Hopkins University, Baltimore, MD
Division of Hematologic Malignancy, Department of Oncology, Johns Hopkins University, Baltimore, MD
Division of Hematologic Malignancy, Department of Oncology, Johns Hopkins University, Baltimore, MD
Division of Hematologic Malignancy, Department of Oncology, Johns Hopkins University, Baltimore, MD
Division of Hematologic Malignancy, Department of Oncology, Johns Hopkins University, Baltimore, MD
Division of Hematologic Malignancy, Department of Oncology, Johns Hopkins University, Baltimore, MD
Division of Hematologic Malignancy, Department of Oncology, Johns Hopkins University, Baltimore, MD
Division of Hematologic Malignancy, Department of Oncology, Johns Hopkins University, Baltimore, MD
Division of Hematologic Malignancy, Department of Oncology, Johns Hopkins University, Baltimore, MD
Division of Hematologic Malignancy, Department of Oncology, Johns Hopkins University, Baltimore, MD
Division of Hematologic Malignancy, Department of Oncology, Johns Hopkins University, Baltimore, MD
Division of Hematologic Malignancy, Department of Oncology, Johns Hopkins University, Baltimore, MD
Division of Hematologic Malignancy, Department of Oncology, Johns Hopkins University, Baltimore, MD
Division of Hematologic Malignancy, Department of Oncology, Johns Hopkins University, Baltimore, MD
Division of Hematologic Malignancy, Department of Oncology, Johns Hopkins University, Baltimore, MD
Division of Hematologic Malignancy, Department of Oncology, Johns Hopkins University, Baltimore, MD
Division of Hematologic Malignancy, Department of Oncology, Johns Hopkins University, Baltimore, MD
Division of Hematologic Malignancy, Department of Oncology, Johns Hopkins University, Baltimore, MD
Division of Hematologic Malignancy, Department of Oncology, Johns Hopkins University, Baltimore, MD
Division of Hematologic Malignancy, Department of Oncology, Johns Hopkins University, Baltimore, MD
Division of Hematologic Malignancy, Department of Oncology, Johns Hopkins University, Baltimore, MD, USA; Section of Hematology/Oncology, Department of Medicine, Baylor College of Medicine, Houston, TX
Division of Biostatistics and Bioinformatics, Department of Oncology, Johns Hopkins University, Baltimore, MD
Division of Hematologic Malignancy, Department of Oncology, Johns Hopkins University, Baltimore, MD
Division of Hematologic Malignancy, Department of Oncology, Johns Hopkins University, Baltimore, MD
Haematologica Early view May 8, 2025 https://doi.org/10.3324/haematol.2025.287433
Navigate
For Authors
For Reviewers
For Advertisers
Education
Privacy
More
Copyright © 2025 by the Ferrata Storti Foundation | Web design ￫ | Development ￫
ISSN 0390-6078 print | ISSN 1592-8721 online